Three-Drug shield aims to protect cancer patients after risky transplants
NCT ID NCT05621759
Summary
This study is testing a new combination of three drugs to prevent a dangerous complication called graft-versus-host disease (GVHD) after a half-matched stem cell transplant for blood cancers. The trial involves 27 adults receiving a transplant from a partially matched family donor. Researchers hope this drug regimen will better control the immune system to prevent GVHD while still allowing the transplant to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.